Targeting CXCL5 in Pancreatic Cancer Cells Inhibits Cancer Xenograft Growth by Reducing Proliferation and Inhibiting...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic cancer (PC) is a highly lethal malignancy with poor survival rates.
• C-X-C ligand 5 (CXCL5) is a chemokine implicated in various cancers, but its role in PC progression is unclear.

Purpose of the Study:

• To investigate the role and prognostic significance of CXCL5 in pancreatic cancer progression.

Main Methods:

• Analyzed CXCL5 expression in PC tissues and cell lines using databases, immunohistochemistry, and Western blotting.
• Conducted in vitro experiments to assess the impact of CXCL5 on PC cell proliferation, migration, and epithelial-mesenchymal transition (EMT).
• Performed in vivo xenograft studies to evaluate the effect of CXCL5 knockdown on tumor growth.

Main Results:

• CXCL5 expression is significantly elevated in PC tissues and correlates with poor patient prognosis.
• Overexpression of CXCL5 enhances PC cell proliferation, migration, and EMT markers (SNAI2, TWIST1).
• Knockdown of CXCL5 inhibits PC cell growth, migration, and EMT in vitro and reduces tumor growth in vivo.

Conclusions:

• High CXCL5 expression is a predictor of poor prognosis in pancreatic cancer patients.
• CXCL5 promotes pancreatic cancer cell growth and EMT.
• Targeting CXCL5 presents a potential therapeutic strategy for pancreatic cancer.